We evaluated the clinical implication of Resection A surgery retrospectively to identify whether quality of surgery can be used as a selection factor for adjuvant therapy in patients with gastric cancer. Methods: Prognosis of 902 patients with gastric cancer who underwent Resection A surgery was evaluated. Results: Among all discharged patients, 77 patients (8.5%) died of recurrent disease, 55 patients (6.1%) died without recurrent disease. Five-year survival rate of all discharged patients was 91.6% and 10-year survival rate 87.1%. Statistically significant prognostic factors were depth of invasion (P＜0.001), lymph node metastasis (P＜ 0.001), stage (P＜0.001), tumor location (P=0.036) and size (P=0.001), extent of gastric resection (P＜0.001), and chemotherapy (P＜0.001) on univariate analyses. However, depth of invasion (P=0.001), lymph node metastasis (P＜0.001), and total gastrectomy (P＜0.001) emerged as statistically significant poor prognostic factor on a multivariate analysis. Adjuvant chemotherapy did not increase the survival rate of patients after Resection A surgery, even in patients with stage II disease. 
INTRODUCTION
There is general consensus that the anatomical extent of gastric cancer is an independent prognostic factor. This has been shown for depth of tumor invasion, involvement of regional lymph nodes and presence of distant metastasis Therefore, even after what is felt to be a "curative" R0 gastrectomy, disease recurs in both regional and/or distant sites. Rationally, patients with early stage gastric cancers have a good to excellent chance of cure with surgery alone.
However, patients with more advanced stages, even if all visible disease has been resected with negative microscopical However, 5-fluorouracil and cisplatin were administered postoperatively in some cases at the patients' request.
The proportions of patients with a given characteristic were compared by the chi-square test. Survival for all discharged patients was calculated from the date of operation until death or last date of follow-up, and Kaplan-Meier survival curves were plotted and compared by the log-rank test. A multivariate analysis was done by the Cox proportional hazards model. The differences were judged to be significant with a P-value of ＜0.05. (Table 3) .
Survival rates for adjuvant chemotherapy adjusted for stage are shown in Table 4 . Adjuvant chemotherapy did not increase survival rate of patients after Resection A surgery even in patients with stage II disease (Fig. 1 ).
DISCUSSION
The prognosis for patients with gastric cancer is, to a large extent, dependent on the extent of disease at the time of diagnosis.(6) Our results also showed that the depth of tumor invasion and lymph node metastasis were strong prognostic indicators even after Resection A surgery.
A curative tumor resection must still be recognized as the most powerful prognostic variable of treatment-related factors. The optimal surgical management of gastric cancer must be tailored to the extent and location of disease. In the absence of distant metastatic spread, an aggressive surgical procedure to achieve macroscopically and microscopically complete surgical resection of tumor is justified.
There is consensus that the quality of the resection is relevant to survival. Allgayer and colleagues reported that the hospital was an independent prognostic factor with a higher probability of survival for patients operated in centers with a broad experience in oncological surgery. (2) Even after what is felt to be a curative gastrectomy, disease recurs in both regional and/or distant sites in the majority of patients with stage II or III gastric cancers.
Efforts to improve these poor results have focused on developing effective pre-and postoperative systemic and regional adjuvant therapies. There are a few reports on the effectiveness of adjuvant chemotherapy for gastric cancer. (7) (8) (9) It is important to identify patients with apparent early-stage disease who will not be cured by surgery alone and, con- In conclusion, most patients survive without recurrent disease after Resection A surgery for gastric cancer and chemotherapy did not increase survival rate after Resection A surgery. In selecting the patients for adjuvant therapy, both the stage of gastric cancer and the quality of surgery should be considered.
